Fifth joint meeting of J-CaP and CaPSURE: Advancing the global understanding of prostate cancer and its management

Japanese Journal of Clinical Oncology

Volumn 42, Issue 3, 2012, Pages 226-236

  Akaza, Hideyuki ^a   Carroll, Peter ^b   Cooperberg, Matthew R ^c   Hinotsu, Shiro ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Androgen deprivation therapy; J CAPRA; Overall survival; Prostate cancer; Risk stratification

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CHINA; HUMAN; INDONESIA; JAPAN; KOREA; MEDICAL INFORMATION; OUTCOME ASSESSMENT; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; RISK ASSESSMENT; STUDY DESIGN; SYSTEMATIC ERROR;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84857946027     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr194     Document Type: Article

References (27)

1. Akaza H, Usami M, Hinotsu S, Ogawa O, Kagawa S, Kitamura T, et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol 2004;34:329-36.
2. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a Phase 3, double-blind, randomized study for survival. Cancer 2009;115:3437-45.
3. American Urological Association. Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinicalguidelines/main-reports/proscan07/content.pdf.
4. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011;29:235-41.
5. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009;27:4306-13.
6. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28:1117-23.
7. Cooperberg MR, Smith A, Odisho AY, Carroll PR, Litwin MS, Saigal CS. Contemporary nationally-representative trends in treatment for localized prostate cancer. Abstract presented at the American Urological Association Annual Meeting, Washington DC, May 2011.
8. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011 (Epub ahead of print).
9. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
10. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
11. Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, et al. European Association of Urology: Guidelines on Prostate Cancer, 2010. Available at: http://www.uroweb.org/gls/pdf/Prostate%20Cancer%202010.pdf.
12. Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, et al. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol 2007;37:775-81.
13. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
14. Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide longterm control or possible cure of localized prostate cancer? Urology 2002;60:115-9.
15. Labrie F. Blockade of testicular and adrenal androgens. Nat Rev Urol 2011;8:73-80.
16. Ministry for Heath, Welfare and Family Affairs. Annual report of cancer incidence (2006) and survival (1993-2006) in Korea; 2009.
17. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology-Prostate Cancer. 2011. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
18. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Asia Consensus Statement-Prostate Cancer. 2011. Available at: http://www.nccn-asia.org/pdf/2010_Prostate_Cancer.pdf.
19. National Statistical Office. 2009. Available at: http://kosis.nso.go.kr (14 January 2010, date last accessed).
20. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8.
21. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 2011 (Epub ahead of print).
22. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
23. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006;98:839-45.
24. Smith DC, Smith MR, Small EJ, Sweeney C, Kurzrock R, Gordon MS, et al. Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. Presented at the ASCO Genitourinary Cancers Symposium, Orlando, FL, 2011. Abstract 127.
25. Tanaka N, Fujimoto K, Hirayama A, Samma S, Momose H, Kaneko Y, et al. The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-Oncological Research Group registration. BMC Urol 2011;11:6.
26. The Korean Urological Oncology Society. Clinical Guidelines on Prostate Carcinoma. 2nd edn. 2009. Available at: http://www.kuos.or.kr.
27. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-24.